STOCK TITAN

Bristol-Myers Squibb Co. (BMY) Stock Price, News & Analysis

BMY NYSE
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
2 252 sessions, November 17, 2025 to November 17, 2026
Largest daily move
+5.6% close of December 3, 2025
1-year change
+31.1% closing prices, November 17, 2025 to November 17, 2026
1-month change
+2.7% closing prices, October 16, 2026 to November 17, 2026

Company Description

Bristol-Myers Squibb Company (NYSE: BMY) is a global biopharmaceutical company in the pharmaceutical preparation manufacturing industry. According to company disclosures, its mission is to discover, develop and deliver medicines that help patients prevail over serious diseases. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, reflecting an established presence in public capital markets.

Bristol Myers Squibb focuses on therapies for serious conditions across several therapeutic areas. Company communications describe a strong emphasis on cardiovascular disease, oncology and immune-related disorders. In particular, the firm highlights immuno-oncology as a key area of drug development, with immuno-oncology medicines positioned as important treatment options in multiple cancer types. The company also notes that a significant portion of its sales are generated in the United States.

Core business and therapeutic focus

The company states that it discovers, develops and markets drugs for cardiovascular conditions, cancer and immune disorders. Within cardiovascular disease, Bristol Myers Squibb co-promotes Eliquis (apixaban), an oral anticoagulant used to reduce the risk of stroke and blood clots in adults with certain types of atrial fibrillation, to help prevent and treat deep vein thrombosis and pulmonary embolism in adults, and to treat and reduce the risk of recurrent venous thromboembolism in children from birth and older after initial anticoagulant treatment. Eliquis is described as a widely prescribed oral blood thinner in the United States.

In oncology and hematology, Bristol Myers Squibb has built a portfolio that includes immuno-oncology agents and cell therapies. Opdivo (nivolumab), a programmed death-1 (PD-1) immune checkpoint inhibitor, is described as an important treatment option across multiple cancers, with regulatory approvals in numerous tumor types such as melanoma, non-small cell lung cancer, classical Hodgkin lymphoma, renal cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal and gastroesophageal cancers and others, based on specific indications outlined in prescribing information. The company also markets the Opdivo plus Yervoy (ipilimumab) combination regimen in several settings.

In cell therapy, Bristol Myers Squibb develops and commercializes Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy. Breyanzi is indicated in the United States for adult patients with certain relapsed or refractory large B-cell lymphomas after specified prior therapies, as well as for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma after defined prior lines of systemic therapy. Company materials emphasize that Breyanzi is administered as a one-time infusion following a multi-step treatment process that includes T cell collection, genetic modification, lymphodepletion and post-infusion monitoring.

Pipeline and research areas

Bristol Myers Squibb reports active research and development programs across hematology, oncology, cardiovascular disease and neuroscience. In hematology and lymphoma, the company is advancing targeted protein degradation agents such as the investigational CELMoD agent golcadomide and the BCL6 ligand-directed degrader BMS-986458, with clinical data presented in aggressive B-cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. These programs are being studied in combination with established regimens such as R-CHOP and rituximab, as well as in monotherapy settings in relapsed or refractory non-Hodgkin lymphoma.

In cardiology, Bristol Myers Squibb develops Camzyos (mavacamten), described as a selective, reversible, allosteric inhibitor of cardiac myosin that targets the pathophysiology of hypertrophic cardiomyopathy by reducing left ventricular outflow tract obstruction and improving cardiac filling pressures in obstructive hypertrophic cardiomyopathy (oHCM). Camzyos is indicated in the United States for adults with symptomatic New York Heart Association class II–III oHCM and has been studied extensively in clinical trials. The company recently announced positive topline results from the Phase 3 SCOUT-HCM trial, the first randomized, placebo-controlled study of a cardiac myosin inhibitor in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

In neuroscience, Bristol Myers Squibb is advancing Cobenfy, which is described as a treatment for schizophrenia in adults and is being evaluated in the ADEPT clinical program for psychosis associated with Alzheimer’s disease. The ADEPT-2 Phase 3 trial is a multicenter, randomized, double-blind, placebo-controlled study assessing safety and efficacy in psychosis associated with Alzheimer’s disease dementia, with endpoints focused on neuropsychiatric symptom scales and clinical global impression measures.

Collaborations and external innovation

The company supplements its internal research with collaborations. For example, Bristol Myers Squibb has a multi-target collaboration with Terray Therapeutics that uses Terray’s EMMI platform, which combines high-throughput chemical experimentation with AI-driven analysis to accelerate small molecule discovery. This collaboration is described as aiming to identify and optimize novel molecules for difficult-to-drug targets in areas of significant unmet medical need.

Regulatory and market footprint

Bristol Myers Squibb’s products are approved in multiple countries and regions, as reflected in company statements. Camzyos is noted as being approved by regulatory bodies in more than 50 countries and regions across five continents for adult symptomatic obstructive hypertrophic cardiomyopathy, and Opdivo is described as approved in more than 65 countries, including the United States, the European Union, Japan and China. Breyanzi has approvals in the United States and several other jurisdictions, including Japan, the European Union, Switzerland, Israel, the United Kingdom and Canada for specified lymphoma indications.

The company’s securities filings confirm that Bristol-Myers Squibb Company is the parent guarantor of multiple series of euro-denominated senior notes issued by a wholly owned Irish subsidiary, BMS Ireland Capital Funding Designated Activity Company. These notes, along with various U.S.-listed notes and Celgene contingent value rights, are registered on the New York Stock Exchange, underscoring the firm’s use of global debt markets to support its operations and capital allocation activities.

Capital allocation and shareholder returns

Bristol Myers Squibb’s board of directors declares regular dividends on its common and preferred stock. In a recent announcement, the company reported a quarterly dividend on its common stock and noted that it has paid dividends for many consecutive years, with a long history of annual increases. The company also conducts tender offers and other transactions involving its outstanding notes, and issues new debt securities under an indenture structure to manage its capital structure and fund corporate purposes, including repurchases, repayments or redemptions of existing notes.

Risk management and safety programs

Given the nature of its therapies, Bristol Myers Squibb describes extensive safety and risk management programs. For Camzyos, the company highlights a boxed warning for risk of heart failure due to systolic dysfunction and notes that the medicine is available only through the CAMZYOS Risk Evaluation and Mitigation Strategy (REMS) Program, which requires certification of prescribers and pharmacies, patient enrollment and ongoing monitoring. For Eliquis, Opdivo and Breyanzi, the company provides detailed important safety information, including boxed warnings for bleeding risk with Eliquis and for cytokine release syndrome, neurologic toxicities and secondary hematological malignancies with Breyanzi. These disclosures outline monitoring requirements, contraindications, drug interactions and management approaches for adverse events.

Geographic base and corporate identity

Regulatory filings list Bristol-Myers Squibb Company’s principal offices in Princeton, New Jersey. The company identifies itself as a global biopharmaceutical enterprise and emphasizes a mission of transforming patients’ lives through science. Public communications reiterate a focus on bold science, serious diseases and collaboration with healthcare providers and policymakers, including agreements with the U.S. government to improve affordability and access to certain medicines such as Eliquis for Medicaid beneficiaries.

Stock Performance

$61.02
-0.54%
-0.33
After hoursChange vs the $61.35 closeLast updated: at
+31.1%
Performance 1 year
$124.7B

Bristol-Myers Squibb Co. (BMY) closed at $61.35 on November 17, 2026. Over the past 12 months, the price has gained 31.1%.

See what a $1,000 investment in BMY would be worth today

Average down calculator for BMY

BMY Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Bristol-Myers Squibb Co. has 10 recent news articles, with the latest published on . Of the recent coverage, 2 articles coincided with positive price movement and 7 with negative movement. Key topics include clinical trial, AI, earnings, partnership. View all BMY news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
10,549
Shares Sold
3
Transactions
Most Recent Transaction
Haller Julia A (Director) sold 3,800 shares @ $63.31 on November 5, 2026

Insider selling at Bristol-Myers Squibb Co. over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Bristol-Myers Squibb Co. generated $48.2B in revenue in FY2025, retaining a 71.1% gross margin, and net income was $7.1B, reflecting a 14.6% net profit margin. Diluted earnings per share stood at $3.46. The company generated $14.2B in operating cash flow. The current ratio was 1.26, measuring current assets divided by current liabilities.

$48.2B
Revenue (FY2025)
$7.1B
Net Income (FY2025)
$14.2B
Operating Cash Flow

Upcoming Events

NOV
30
November 30, 2026 Marketing

Grant Nomination Deadline

Healthcare professionals may anonymously nominate nonprofits for Bristol Myers Squibb's $1M Champions in Care grants by Nov 30, 2026.
DEC
2026
December 2026 Clinical

ASH annual meeting presentation

Full Phase 3 EXCALIBER‑RRMM results to be presented at the 68th ASH annual meeting in Dec 2026; in-person session and ASH webcast.
JAN
01
January 1, 2027 - December 31, 2030 Operations

Manufacturing campus construction

Construction of a $2.3B multi-modal manufacturing campus at Generation Park, Houston; supports ~2,000 jobs from 2027–2030.
YEAR
2027
2027 Clinical

ALOFT-PPF topline results

Topline results for fully enrolled ALOFT-PPF trial expected early 2027 (Jan–Apr); will inform regulatory engagement and label discussions.
JAN
01
January 1, 2027 Corporate

R&D leadership unification

Cristian Massacesi to lead the unified research and development organization, effective 2027-01-01, consolidating discovery to development.
MAR
2027
March 2027 Corporate

Plenge advisory departure

Robert Plenge will remain in an advisory capacity through March 2027 and depart thereafter; timing given as through March 2027.
MAY
13
May 13, 2027 Regulatory

Mezigdomide PDUFA decision

FDA decision on mezigdomide (MeziKd) NDA for relapsed/refractory multiple myeloma; PDUFA action date 2027-05-13.

Bristol-Myers Squibb Co. has 7 upcoming scheduled events. The next event, "Grant Nomination Deadline", is scheduled for November 30, 2026 (in 13 days). Investors can track these dates to stay informed about potential catalysts that may affect the BMY stock price.

Short Interest History

Last 12 Months

Short interest in Bristol-Myers Squibb Co. (BMY) currently stands at 46.8 million shares, down 6.2% from the previous reporting period, representing 2.3% of the float. Since November 2025, short interest has increased by 38.2%.

Days to Cover History

Last 12 Months

Days to cover for Bristol-Myers Squibb Co. (BMY) currently stands at 4.2 days, up 16.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 78.9%. Across the settlements charted above, it has ranged from 2.0 to 5.8 days.

BMY Company Profile & Sector Positioning

Bristol-Myers Squibb Co. (BMY) operates in the Drug Manufacturers - General industry within the broader Healthcare sector and is listed on the NYSE. Among dividend-paying stocks, BMY ranks #720 by dividend yield.

Investors comparing BMY often look at related companies in the same sector, including Sanofi (SNY), Pfizer Inc. (PFE), GSK plc (GSK), Novo Nordisk A/S (NVO), and Biogen Inc. (BIIB). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate BMY's relative position within its industry.

Frequently Asked Questions

The current stock price of Bristol-Myers Squibb Co. (BMY) is $61.02 in after-hours trading as of November 17, 2026.

The market cap of Bristol-Myers Squibb Co. (BMY) is approximately $124.7B. Learn more about what market capitalization means .

The FY2025 revenue of Bristol-Myers Squibb Co. (BMY) is $48.2B, from its most recent completed fiscal year.

The FY2025 net income of Bristol-Myers Squibb Co. (BMY) is $7.1B, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Bristol-Myers Squibb Co. (BMY) is $3.46 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Bristol-Myers Squibb Co. (BMY) is $14.2B for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Bristol-Myers Squibb Co. (BMY) is 14.6% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The gross profit margin of Bristol-Myers Squibb Co. (BMY) is 71.1% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Bristol-Myers Squibb Co. (BMY), current assets divided by current liabilities, was 1.26 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Bristol-Myers Squibb Co. (BMY) is $34.3B for FY2025, its most recent completed fiscal year.

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and markets prescription medicines for serious diseases. Company materials highlight focus areas such as cardiovascular disease, cancer, immune-related disorders and neuroscience.

The company emphasizes cardiovascular health, hematology and oncology, immuno-oncology and neuroscience. Examples include Eliquis in cardiovascular disease, Opdivo and the Opdivo plus Yervoy regimen in multiple cancers, Camzyos in obstructive hypertrophic cardiomyopathy, Breyanzi in B-cell lymphomas and Cobenfy in neuropsychiatric conditions.

According to its SEC filings, Bristol-Myers Squibb Company’s common stock is listed on the New York Stock Exchange under the ticker symbol BMY.

Eliquis (apixaban) is an oral anticoagulant used in adults to reduce the risk of stroke and blood clots in certain types of atrial fibrillation, to help prevent blood clots after hip or knee replacement surgery, and to treat and reduce the risk of recurrent deep vein thrombosis and pulmonary embolism. It is also indicated in children from birth and older to treat and reduce the risk of recurrent venous thromboembolism after initial anticoagulant treatment.

Camzyos (mavacamten) is a selective, reversible, allosteric inhibitor of cardiac myosin that targets the pathophysiology of hypertrophic cardiomyopathy. It is indicated in the United States for adults with symptomatic New York Heart Association class II–III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms, and has been studied in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM trial.

Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor that helps restore anti-tumor immune responses. It is approved in multiple cancers, including melanoma, non-small cell lung cancer, classical Hodgkin lymphoma, renal cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma and certain esophageal and gastric cancers, based on specific indications described in its prescribing information.

Breyanzi (lisocabtagene maraleucel; liso-cel) is a CD19-directed CAR T cell therapy. A patient’s T cells are collected, genetically reengineered to express a chimeric antigen receptor targeting CD19, and then infused back as a one-time treatment. It is indicated in the United States for adult patients with certain relapsed or refractory large B-cell lymphomas and for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma after specified prior therapies.

The company provides detailed important safety information and boxed warnings where required, describing risks, contraindications and monitoring needs. For example, Camzyos carries a boxed warning for risk of heart failure due to systolic dysfunction and is available only through the CAMZYOS REMS Program, while Breyanzi includes boxed warnings for cytokine release syndrome, neurologic toxicities and secondary hematological malignancies, with specific monitoring and management recommendations.

ADEPT-2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating Cobenfy in subjects with psychosis associated with Alzheimer’s disease dementia. It assesses changes in neuropsychiatric symptom scores and clinical global impression measures, along with safety and tolerability compared with placebo.

The company announced an agreement with the U.S. government under which Eliquis will be provided for free to the Medicaid program for a defined period, along with a donation of Eliquis active pharmaceutical ingredient to the U.S. Strategic Active Ingredient Reserve and other commitments related to pricing approaches and direct-to-patient access for select medicines.